BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

119

Participants

Timeline

Start Date

January 13, 2016

Primary Completion Date

September 2, 2020

Study Completion Date

September 2, 2020

Conditions
B-cell Lymphoid Malignancies
Interventions
DRUG

Zanubrutinib

DRUG

Obinutuzumab

Trial Locations (14)

2217

St George Hospital, Kogarah

3004

The Alfred Hospital, Melbourne

3065

St Vincents Hospital Melbourne, Fitzroy

3144

St Frances Xavier Cabrini Hospital, Malvern

3220

Barwon Health the Geelong Hospital, Geelong

4120

Brisbane Clinic For Lymphoma, Greenslopes

5087

Ashford Cancer Centre Research Northeast, Windsor Gardens

6000

Royal Perth Hospital, Perth

33401

Florida Cancer Specialists East, West Palm Beach

33916

Florida Cancer Specialists Fort Myers, Fort Myers

37205

Tennessee Oncology, Nashville

05505

Asan Medical Center, Seoul

06273

Gangnam Severance Hospital, Yonsei University Health System, Seoul

06351

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BeiGene

INDUSTRY